公开(公告)号：US20060079522A1

公开(公告)日：2006-04-13

申请号：US10962099

申请日：2004-10-08

申请人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

发明人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

IPC分类号： A61K31/5377 ,  A61K31/496 ,  A61K31/4545 ,  C07D403/14 ,  C07D413/14

CPC分类号： C07D211/26 ,  C07D401/12 ,  C07D403/12

摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括给予受试者一定量的本发明化合物。

公开(公告)号：US20060173027A1

公开(公告)日：2006-08-03

申请号：US10518939

申请日：2003-07-03

申请人： Mohammad Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel ,  Kim Andersen

发明人： Mohammad Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel ,  Kim Andersen

IPC分类号： A61K31/4747

CPC分类号： C07D221/20 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D491/10

摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。 本发明还提供了治疗患有尿失禁的受试者的方法。

公开(公告)号：US20060079524A1

公开(公告)日：2006-04-13

申请号：US11230849

申请日：2005-09-20

申请人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

发明人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

IPC分类号： A61K31/5377 ,  A61K31/4545 ,  A61K31/496 ,  C07D413/14 ,  C07D403/14

CPC分类号： C07D211/26 ,  C07D211/34 ,  C07D401/12 ,  C07D403/12

摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

公开(公告)号：US20060079683A1

公开(公告)日：2006-04-13

申请号：US10961432

申请日：2004-10-08

申请人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

发明人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

IPC分类号： C07D413/14 ,  C07D401/14

CPC分类号： C07D211/60 ,  C07D211/26 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14

摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括给予受试者一定量的本发明化合物。

公开(公告)号：US20060079523A1

公开(公告)日：2006-04-13

申请号：US11231601

申请日：2005-09-21

申请人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

发明人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

IPC分类号： A61K31/5377 ,  A61K31/496 ,  A61K31/4545 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14

CPC分类号： C07D401/04 ,  C07D211/26 ,  C07D211/62 ,  C07D401/12 ,  C07D401/14

摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

公开(公告)号：US20080139555A1

公开(公告)日：2008-06-12

申请号：US12028094

申请日：2008-02-08

申请人： Mohammad R. Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

发明人： Mohammad R. Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

IPC分类号： A61K31/4545 ,  A61K31/5377 ,  C07D413/14 ,  C07D401/14 ,  A61P25/24 ,  A61P25/00 ,  A61P3/04 ,  C07D403/14 ,  A61K31/496

CPC分类号： C07D401/04 ,  C07D211/26 ,  C07D211/62 ,  C07D401/12 ,  C07D401/14

摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

公开(公告)号：US07446204B2

公开(公告)日：2008-11-04

申请号：US11230849

申请日：2005-09-20

申请人： Mohammad R. Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

发明人： Mohammad R. Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

IPC分类号： C07D211/14 ,  A61K31/451

CPC分类号： C07D211/26 ,  C07D211/34 ,  C07D401/12 ,  C07D403/12

摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

公开(公告)号：US07335665B2

公开(公告)日：2008-02-26

申请号：US10518939

申请日：2003-07-03

申请人： Mohammad R. Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John E. De Leon ,  John Wetzel ,  Kim Andersen

发明人： Mohammad R. Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John E. De Leon ,  John Wetzel ,  Kim Andersen

IPC分类号： A61K31/438 ,  C07D221/20 ,  C07D491/10

CPC分类号： C07D221/20 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D491/10

摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。 本发明还提供了治疗患有尿失禁的受试者的方法。

公开(公告)号：US07329656B2

公开(公告)日：2008-02-12

申请号：US11231601

申请日：2005-09-21

申请人： Mohammad R. Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

发明人： Mohammad R. Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

IPC分类号： A61K31/4545 ,  A61K31/444 ,  A61K31/5377 ,  C07D211/04 ,  C07D401/04 ,  C07D413/14

CPC分类号： C07D401/04 ,  C07D211/26 ,  C07D211/62 ,  C07D401/12 ,  C07D401/14

摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

摘要翻译： 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

公开(公告)号：US20120302553A1

公开(公告)日：2012-11-29

申请号：US13367065

申请日：2012-02-06

申请人： Thomas Ruhland ,  Garrick P. Smith ,  Benny Bang-Anderson ,  Ask Puschl ,  Ejner Knud Moltzen ,  Kim Andersen

发明人： Thomas Ruhland ,  Garrick P. Smith ,  Benny Bang-Anderson ,  Ask Puschl ,  Ejner Knud Moltzen ,  Kim Andersen

IPC分类号： A61K31/551 ,  A61K31/495 ,  C07D243/08 ,  C07D213/32 ,  C07D241/04 ,  C07D211/20 ,  A61K31/451 ,  A61P25/24 ,  A61P25/22 ,  A61P25/00 ,  C07D295/096 ,  A61K31/4418

CPC分类号： C07D295/145 ,  C07D211/20 ,  C07D211/70 ,  C07D243/08 ,  C07D295/033 ,  C07D295/096

摘要： The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

摘要翻译： 本发明提供由通式I表示的化合物，其中取代基在本申请中定义。 这些化合物可用于治疗情感障碍，包括抑郁症，焦虑症，包括一般焦虑症，惊恐障碍和强迫症。